Cellectis (CLLS) Cash from Financing Activities (2015 - 2026)
Cellectis (CLLS) posted quarterly Cash from Financing Activities of -$4.9 million for Q1 2026, down 19.8% year-over-year from -$6.1 million in Q1 2025, and down 18.36% quarter-over-quarter from -$4.1 million in Q4 2025.
Cellectis (CLLS) Cash from Financing Activities (2015 - 2026) Analysis & Trends
Cellectis' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at -$4.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 19.8% year-over-year to -$4.9 million; the TTM figure through Mar 2026 stood at -$17.6 million (down 124.03% YoY), while the FY2025 annual figure was -$16.8 million, down 118.81% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$4.9 million, down from -$4.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $78.5 million in Q2 2024, with the low at -$13.7 million in Q4 2022.
- The 5-year median for Cash from Financing Activities is $1.7 million (2023), against an average of $8.4 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 862.19% in 2022, then soared 653.5% in 2023.
- Cellectis' Cash from Financing Activities stood at -$13.7 million in 2022, then surged by 403.68% to $41.6 million in 2023, then plunged by 92.97% to $2.9 million in 2024, then slumped by 241.54% to -$4.1 million in 2025, then decreased by 18.36% to -$4.9 million in 2026.
- Business Quant data shows CLLS's Cash from Financing Activities at -$4.9 million in Q1 2026, -$4.1 million in Q4 2025, and -$4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -4.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.90 Mn |
| Mar 31, 2026 | -4.90 Mn |
| Dec 31, 2025 | -4.14 Mn |
| Dec 31, 2025 | -4.14 Mn |
| Sep 30, 2025 | -4.26 Mn |
| Sep 30, 2025 | -4.26 Mn |
| Jun 30, 2025 | -4.27 Mn |
| Jun 30, 2025 | -4.27 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | 78.51 Mn |
| Jun 30, 2024 | 78.51 Mn |
| Mar 31, 2024 | 11.90 Mn |
| Mar 31, 2024 | 11.90 Mn |
| Dec 31, 2023 | 41.58 Mn |
| Dec 31, 2023 | 41.58 Mn |